{"t":"DOCUMENT","c":"","l":0,"ch":[{"t":"CONTAINER","c":"html","l":1,"ch":[{"t":"CONTAINER","c":"head","l":2,"ch":[{"t":"CONTAINER","c":"title","l":3,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":4}]},{"t":"CONTAINER","c":"meta","l":3}]},{"t":"CONTAINER","c":"body","l":2,"ch":[{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"ix:header","l":4,"ch":[{"t":"CONTAINER","c":"ix:hidden","l":5,"ch":[{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"--12-31","l":7}]},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"false","l":7}]},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"0001637715","l":7}]}]},{"t":"CONTAINER","c":"ix:references","l":5,"ch":[{"t":"CONTAINER","c":"link:schemaref","l":6}]},{"t":"CONTAINER","c":"ix:resources","l":5,"ch":[{"t":"CONTAINER","c":"xbrli:context","l":6,"ch":[{"t":"CONTAINER","c":"xbrli:entity","l":7,"ch":[{"t":"CONTAINER","c":"xbrli:identifier","l":8,"ch":[{"t":"SECTION_TITLE","c":"0001637715","l":9}]}]},{"t":"CONTAINER","c":"xbrli:period","l":7,"ch":[{"t":"CONTAINER","c":"xbrli:startdate","l":8,"ch":[{"t":"SECTION_TITLE","c":"2024-10-04","l":9}]},{"t":"CONTAINER","c":"xbrli:enddate","l":8,"ch":[{"t":"SECTION_TITLE","c":"2024-10-04","l":9}]}]}]},{"t":"CONTAINER","c":"xbrli:context","l":6,"ch":[{"t":"CONTAINER","c":"xbrli:entity","l":7,"ch":[{"t":"CONTAINER","c":"xbrli:identifier","l":8,"ch":[{"t":"SECTION_TITLE","c":"0001637715","l":9}]},{"t":"CONTAINER","c":"xbrli:segment","l":8,"ch":[{"t":"CONTAINER","c":"xbrldi:explicitmember","l":9,"ch":[{"t":"SECTION_TITLE","c":"dei:FormerAddressMember","l":10}]}]}]},{"t":"CONTAINER","c":"xbrli:period","l":7,"ch":[{"t":"CONTAINER","c":"xbrli:startdate","l":8,"ch":[{"t":"SECTION_TITLE","c":"2024-10-04","l":9}]},{"t":"CONTAINER","c":"xbrli:enddate","l":8,"ch":[{"t":"SECTION_TITLE","c":"2024-10-04","l":9}]}]}]}]}]}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"UNITED STATES","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"SECURITIES AND EXCHANGE COMMISSION","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Washington, D.C. 20549","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"CONTAINER","c":"div","l":5,"ch":[{"t":"PARAGRAPH","c":"p","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":7},{"t":"CONTAINER","c":"ix:nonnumeric","l":7,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"CONTAINER","c":"div","l":5,"ch":[{"t":"PARAGRAPH","c":"p","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"CURRENT REPORT","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Pursuant to Section 13 or 15(d)","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"of The Securities Exchange Act of 1934","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"October 4, 2024","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"CONTAINER","c":"div","l":5,"ch":[{"t":"PARAGRAPH","c":"p","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"ONKURE THERAPEUTICS, INC.","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"ONKURE THERAPEUTICS, INC.","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"(Exact name of registrant as specified in its charter)","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"CONTAINER","c":"div","l":5,"ch":[{"t":"PARAGRAPH","c":"p","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Delaware","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"001-40315","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"47-2309515","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"(State or other jurisdictionof incorporation)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(CommissionFile Number)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(I.R.S. EmployerIdentification No.)","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"6707 Winchester Circle,Suite 400","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Boulder,Colorado","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"80301","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"(Address of principal executive offices)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(Zip code)","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"720","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"307-2892","l":7},{"t":"CONTAINER","c":"ix:nonnumeric","l":7,"ch":[{"t":"SECTION_TITLE","c":"307-2892","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"(Registrant’s telephone number, including area code)","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Reneo Pharmaceuticals, Inc.","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"Reneo Pharmaceuticals, Inc.","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"18575 Jamboree Road","l":7}]},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"275-S","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"Irvine","l":7}]},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"CA","l":7}]},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"92612","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"(Former name or former address, if changed since last report)","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"CONTAINER","c":"div","l":5,"ch":[{"t":"PARAGRAPH","c":"p","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"☐","l":8},{"t":"TABLE_CELL","c":"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"☐","l":8},{"t":"TABLE_CELL","c":"Soliciting material pursuant to Rule14a-12under the Exchange Act (17 CFR240.14a-12)","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"☐","l":8},{"t":"TABLE_CELL","c":"Pre-commencementcommunications pursuant to Rule14d-2(b)under the Exchange Act (17 CFR240.14d-2(b))","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"☐","l":8},{"t":"TABLE_CELL","c":"Pre-commencementcommunications pursuant to Rule13e-4(c)under the Exchange Act (17 CFR240.13e-4(c))","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Securities registered pursuant to Section 12(b) of the Act:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Title of each class","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"TradingSymbol(s)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Name of each exchangeon which registered","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Class A Common Stock, par value $0.0001 per share","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"OKUR","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"The Nasdaq Stock Market LLC","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"12b-2","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"(§240.12b-2","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"☒","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"☐","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Introductory Note","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Closing Date","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Closing Date","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Reneo","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Reneo","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Merger Agreement","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Merger Agreement","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Merger Sub I","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Merger Sub I","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Merger Sub II","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Merger Sub II","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Legacy OnKure","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Legacy OnKure","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Reverse Stock Split","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Reverse Stock Split","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Merger","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Merger","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Combined Company","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Combined Company","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"OnKure","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"OnKure","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"we","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"we","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"us","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"us","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"our","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"our","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Company","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Company","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Board","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Board","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Closing","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Closing","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Transactions","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Transactions","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Subscription Agreement","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Subscription Agreement","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"PIPE Investors","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"PIPE Investors","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Class","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Class","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"A Common Stock","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"A Common Stock","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Concurrent PIPE Investments","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Concurrent PIPE Investments","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item 2.01. Completion of Acquisition or Disposition of Assets.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Special Meeting","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Special Meeting","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"2024 Plan","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"2024 Plan","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"2024 ESPP","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"2024 ESPP","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"On October 4, 2024, the parties to the Merger Agreement completed the Merger and the other transactions contemplated thereby in accordance with the terms of the Merger Agreement. Effective at 4:01 p.m. eastern time on October 4, 2024, the Company effected the Reverse Stock Split at a ratio of 1:10; effective at 4:02 p.m. eastern time on October 4, 2024, the Company changed its name to “OnKure Therapeutics, Inc.” and reclassified each share of Reneo common stock to Class A Common Stock; and effective at 4:15 p.m. eastern time on October 4, 2024 (the “Effective Time”), the parties to the Merger Agreement consummated the Merger.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Common","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Common","l":8}]}]},{"t":"CONTAINER","c":"span","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Exchange Ratio","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Exchange Ratio","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Preferred","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Preferred","l":8}]}]},{"t":"CONTAINER","c":"span","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Exchange Ratio","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Exchange Ratio","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-voting","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"2","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Class","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Class","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"B Common Stock","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"B Common Stock","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Common Stock","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Common Stock","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"RSUs","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"RSUs","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Nasdaq","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Nasdaq","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Proxy Statement/Prospectus","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Proxy Statement/Prospectus","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"S-4","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"No. 333-280369),","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"SEC","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"SEC","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"FORM 10 INFORMATION","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Forward-Looking Statements","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Forward-Looking Statements","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that we have anticipated. Forward-looking statements include, but are not limited to, statements concerning the following:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"risks associated with the possible failure to realize certain anticipated benefits of the Transactions, including with respect to future financial and operating results;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"unexpected costs, charges or expenses resulting from the Transactions;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"3","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the potential for, and uncertainty associated with the outcome of, legal proceedings instituted against the Combined Company or its directors or officers related to the Transactions;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"risks related to OnKure’s early stage of development; the uncertainties associated with OnKure’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the significant net losses each of Reneo and Legacy OnKure has incurred since inception;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the Combined Company’s ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the timing of the availability of data from the Combined Company’s clinical trials;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the outcome of preclinical testing and clinical trials of the Combined Company’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the Combined Company’s plans to research, develop and commercialize its current and future product candidates;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the clinical utility, potential benefits and market acceptance of the Combined Company’s product candidates;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the Combined Company’s ability to attract, hire, and retain skilled executive officers and employees;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the Combined Company’s ability to protect its intellectual property and proprietary technologies;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the Combined Company’s reliance on third parties, contract manufacturers, and contract research organizations;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the possibility that the Combined Company may be adversely affected by other economic, business, or competitive factors; risks associated with changes in applicable laws or regulations;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the risks and uncertainties identified from time to time in documents filed or to be filed with the SEC by the Combined Company; and","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"other risks.","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, including but not limited to those described under the heading “Risk Factors” beginning on page 36 of the Proxy Statement/Prospectus, which is incorporated herein by reference, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Business","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Business","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"from non-selective inhibition","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"the non-mutated (or","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"utilizing x-ray crystallography","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"PI3K","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"PI3K","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"candidate, OKI-219, is","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"PI3K","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"PI3K","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"H1047R","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"H1047R","l":8},{"t":"CONTAINER","c":"sup","l":8,"ch":[{"t":"SECTION_TITLE","c":"H1047R","l":9}]}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"PI3K","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"PI3K","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"WT","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"WT","l":8},{"t":"CONTAINER","c":"sup","l":8,"ch":[{"t":"SECTION_TITLE","c":"WT","l":9}]}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"of OKI-219 in","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"HR+","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"HR+","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"HER2-","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"HER2-","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"HER2+","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"HER2+","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"4","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"of OKI-219 by","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"tumors. OKI-219 is","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"a first-in-human Phase","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"a first-in-human Phase","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"particular, non-selective inhibition","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"sup","l":6,"ch":[{"t":"SECTION_TITLE","c":"H1047R","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"is non-selective for","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"candidate, OKI-219. OKI-219 targets","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"candidate, OKI-219. OKI-219 targets","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"approximately 80-fold selectivity","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"of OKI-219 in","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"We are also developing next-generation product candidates designed to selectively target not just H1047R, but also to inhibit H1047L and H1047K mutations, providing an opportunity to potentially broaden the patient population and address possible resistance mechanisms. Additional programs at the Combined Company include targeting other highly prevalent PI3Kα mutations such as E542K and E545K. Over time, the Combined Company aims to design and develop product candidates that effectively target all of the key oncogenic mutations in PI3Kα.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Our Team","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"We have assembled a leadership team with extensive experience in drug discovery and development, with particular strengths in the discovery of small molecule protein kinase inhibitors. We believe that the team’s shared history at prior successful drug development organizations provides a promising opportunity for driving efficient drug development, especially for this class of drugs.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Nicholas Saccomano, Ph.D.,","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"CEO","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"CEO","l":8}]}]},{"t":"CONTAINER","c":"sup","l":6,"ch":[{"t":"SECTION_TITLE","c":"®","l":7}]},{"t":"CONTAINER","c":"sup","l":6,"ch":[{"t":"SECTION_TITLE","c":"®","l":7}]},{"t":"CONTAINER","c":"sup","l":6,"ch":[{"t":"SECTION_TITLE","c":"®","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"5","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Dylan Hartley, Ph.D.","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Samuel Agresta, M.D.","l":7}]},{"t":"CONTAINER","c":"sup","l":6,"ch":[{"t":"SECTION_TITLE","c":"®","l":7}]},{"t":"CONTAINER","c":"sup","l":6,"ch":[{"t":"SECTION_TITLE","c":"®","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"and ado-trastuzumab emtansine,","l":7}]},{"t":"CONTAINER","c":"sup","l":6,"ch":[{"t":"SECTION_TITLE","c":"®","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Jason Leverone, C.P.A.","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The Combined Company is supported by both a scientific advisory board and a board of directors with extensive experience in drug development and building public companies.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The Combined Company’s Clinical Pipeline","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"advancing OKI-219 in","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"img","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Our business is further described in the Proxy Statement/Prospectus in the section titled “OnKure Business” beginning on page 224 of the Proxy Statement/Prospectus and that information is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Risk Factors","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Risk Factors","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The risk factors related to the Combined Company’s business and operations and the Transactions are set forth in the Proxy Statement/Prospectus in the section titled “Risk Factors” beginning on page 36 of the Proxy Statement/Prospectus and that information is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Audited Financial Statements","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Audited Financial Statements","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The audited financial statements as of and for the years ended December 31, 2023 and 2022 of Legacy OnKure set forth in Exhibit 99.1 hereto are incorporated herein by reference and have been prepared in accordance with U.S. generally accepted accounting principles and pursuant to the regulations of the SEC.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"6","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"These audited financial statements should be read in conjunction with the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included herein.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Unaudited Financial Statements","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Unaudited Financial Statements","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The unaudited financial statements as of and for the three and six months ended June 30, 2024 of Legacy OnKure set forth in Exhibit 99.2 hereto are incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"These unaudited financial statements should be read in conjunction with the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included herein.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Unaudited Pro Forma Condensed Combined Financial Information","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Unaudited Pro Forma Condensed Combined Financial Information","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The unaudited pro forma condensed combined financial information of the Combined Company for the three and six months ended June 30, 2024 and year ended December 31, 2023 is set forth in Exhibit 99.3 hereto and is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Management’s Discussion and Analysis of Financial Condition and Results of Operations","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Management’s Discussion and Analysis of Financial Condition and Results of Operations","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"10-K","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"10-K/A,","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"10-K,","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"10-Q","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"10-Q,","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Management’s discussion and analysis of the financial condition and results of operation of Legacy OnKure as of and for the year ended December 31, 2023 and the three and six months ended June 30, 2024 is set forth below.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K.","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K.","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Overview","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"candidate, OKI-219, is","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"PI3K","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"PI3K","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"PI3K","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"PI3K","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"H1047R","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"H1047R","l":8},{"t":"CONTAINER","c":"sup","l":8,"ch":[{"t":"SECTION_TITLE","c":"H1047R","l":9}]}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"on non-mutated (or","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"PI3K","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"PI3K","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"WT","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"WT","l":8},{"t":"CONTAINER","c":"sup","l":8,"ch":[{"t":"SECTION_TITLE","c":"WT","l":9}]}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"”). OKI-219 is","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"a first-in-human Phase","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"a first-in-human Phase","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"to OKI-219, we","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Legacy OnKure was incorporated in the State of Delaware in 2011 and we are headquartered in Boulder, Colorado. Since our inception, we have devoted substantially all of our resources to research and development activities, business planning, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these activities.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"7","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":".","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"To date, OnKure has funded its operations primarily through private placements of OnKure common stock, OnKure preferred stock and convertible debt. As of June 30, 2024, OnKure had cash and cash equivalents of $18.6 million. After giving effect to the Merger and the Concurrent PIPE Investments, we believe the resulting cash resources are sufficient to fund our planned operations into the fourth quarter of 2026.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"As of June 30, 2024, OnKure had an accumulated deficit of $125.7 million. OnKure incurred losses and negative cash flows from operations since inception, including net losses of $35.3 million and $29.5 million for the years ended December 31, 2023 and 2022, respectively. OnKure’s net losses for the periods ended June 30, 2024 and 2023 were $23.7 million and $16.9 million, respectively. We expect that our operating losses and negative operating cash flows will continue for the foreseeable future as we develop our product candidates.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on a variety of factors including the timing and scope of its research and development activities. We expect our expenses and capital requirements will increase substantially in connection with our ongoing activities as we:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"advance theOKI-219 programthrough clinical development;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"advance the development of other small-molecule research-stage programs;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"expand our pipeline of product candidates through our own research and development efforts;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"seek to discover and develop additional product candidates;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"seek regulatory approvals for any product candidates that successfully complete clinical trials;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"contract to manufacture any approved product candidates;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"expand our clinical, scientific, management and administrative teams;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets andknow-how;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"implement operational, financial and management systems; and","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"operate as a public company.","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"We do not have any products approved for commercial sale, have not generated any revenue from product sales or other sources and cannot provide assurance that we will ever generate positive cash flows from operating activities. Our ability to generate product revenue sufficient to achieve and maintain profitability will depend upon the successful development and eventual commercialization of one or more of OnKure’s product","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"8","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"candidates, which is uncertain and expected to take many years. We will therefore require substantial additional capital to develop these product candidates and support our continuing operations. Accordingly, until such time that we can generate a sufficient amount of revenue from product sales or other sources, if ever, we expect to finance our operations through private or public equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties. However, we may be unable to raise additional capital from these sources on favorable terms, or at all. Our failure to obtain sufficient capital on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, including requiring us to delay, reduce or curtail our research, product development or future commercialization efforts. We may also be required to license rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Recent Developments","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The Merger and Concurrent PIPE Investments","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"The Merger and Concurrent PIPE Investments","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"On May 10, 2024, we entered into the Merger Agreement, pursuant to which Legacy OnKure merged with and into Radiate Merger Sub I at the Effective Time on October 4, 2024, with Legacy OnKure continuing after the Merger as the surviving company and a wholly-owned subsidiary of the Company. At the Effective Time, each outstanding share of Legacy OnKure capital stock was converted into the right to receive shares of Class A Common Stock or Class B Common Stock, as set forth in the Merger Agreement. Upon closing of the Merger, the Company was renamed “OnKure Therapeutics, Inc.” and will continue to be listed on Nasdaq.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Under the exchange ratio formulas in the Merger Agreement, immediately following the Effective Time, (i) (a) each then-outstanding share of Legacy OnKure common stock was converted into the right to receive 0.023596 shares of Class A Common Stock based on the Common Exchange Ratio, and (b) each then-outstanding share of Legacy OnKure preferred stock was converted into the right to receive 0.144794 shares of Class A Common Stock based on the Preferred Exchange Ratio; provided that a holder of Legacy OnKure preferred stock chose to receive 686.527 shares that it would otherwise have received in the form of Class A Common Stock in an equal number of shares of Class B Common Stock, (ii) each then-outstanding option to purchase shares of Legacy OnKure common stock was assumed by the Company and converted into an option to purchase Class A Common Stock based on the Common Exchange Ratio, subject to adjustments set forth in the Merger Agreement, and (iii) each then-outstanding RSU of Legacy OnKure corresponding to shares of Legacy OnKure preferred stock was assumed by the Company and converted into RSUs of the Company covering 213,254 shares of Class A Common Stock based on the Preferred Exchange Ratio, subject to adjustments set forth in the Merger Agreement. Each share of Reneo common stock, each option to purchase shares of Reneo common stock and each RSU award covering shares of Reneo common stock that was issued and outstanding as of immediately prior to the Effective Time remained issued and outstanding in accordance with its terms and such shares, options and RSUs, subject to the Reverse Stock Split, were reclassified as Class A Common Stock but were otherwise unaffected by the Merger; provided that, to the extent not previously vested, all such options and RSUs held by Reneo’s directors and executive officers vested at the Effective Time.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Concurrently with the execution of the Merger Agreement, Reneo entered into the Subscription Agreement with the PIPE Investors, pursuant to which the PIPE Investors subscribed for and purchased an aggregate of 2,839,005 shares of Class A Common Stock at a price of approximately $22.895 per share for aggregate gross proceeds of approximately $65.0 million.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Basis of Presentation","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K,","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"U.S. GAAP","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"U.S. GAAP","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"9","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Components of Statements of Operations and Comprehensive Loss","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Revenue","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Revenue","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"To date, OnKure has not generated any revenue and it does not expect to generate any revenue from the sale of products or from other sources in the foreseeable future.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Operating Expenses","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Operating Expenses","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Research and Development","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Research and Development","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Research and development expenses account for a significant portion of OnKure’s operating expenses and consist primarily of expenses incurred in connection with the discovery and development of its product candidates.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Research and development expenses consist of costs incurred for the research and development of OnKure’s programs and product candidates, which include:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"employee-related expenses, including salaries, severance, retention, benefits, insurance and share-based compensation expense;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"expenses incurred under agreements with contract research organizations (“CROs”), which are companies that assist in managing OnKure’s clinical trials, other clinical trial-related vendors and clinical consultants;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the costs of acquiring, developing, and manufacturing and testing clinical and preclinical materials, including costs incurred under agreements with contract manufacturing organizations (“CMOs”);","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"costs associated withnon-clinicalactivities and regulatory operations; and","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"facilities, depreciation, market research and other expenses, which include allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory supplies.","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-refundable","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time-consuming. As OnKure initiates new clinical trials, its research and development expenses may increase. Product candidates in later stages of development generally have higher development costs than those in earlier stages. As a result, OnKure expects that its research and development expenses will increase substantially over the next several years as it advances product candidates through preclinical studies into and through clinical trials, continues to discover and develop additional product candidates, undertakes activities to expand, maintain, protect and enforce its intellectual property portfolio, and hires additional research and development personnel.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Successful development of product candidates is highly uncertain and may not result in approved products. The probability of success for each product candidate may be affected by numerous factors, including clinical data, preclinical data, competition, manufacturability and commercial viability. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. OnKure anticipates that it will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to its ability to enter strategic alliances with respect to each program or product candidate, the scientific and clinical success of each product candidate and ongoing assessments as to each product candidate’s commercial potential. OnKure will need to raise additional capital and may seek strategic alliances in the future to advance its various programs.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Selling, General and Administrative","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Selling, General and Administrative","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"General and administrative expenses consist primarily of salaries, bonuses and related benefits, share-based compensation and severance and retention benefits related to OnKure’s executive, finance and administrative functions, professional fees for auditing, tax, consulting and legal services, as well as insurance, board of director compensation, consulting and other administrative expenses. OnKure recognizes general and administrative expenses in the periods in which they are incurred.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"10","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"OnKure expects that its general and administrative expenses will increase over the next several years as it hires additional personnel to support the growth of its business. In addition, the Combined Company will incur significant additional expenses associated with being a public company, including expenses related to accounting, audit, legal, regulatory, public company reporting and compliance, director and officer insurance, investor and public relations and other administrative and professional services.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Other Income","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Other Income","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Interest Income","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Interest Income","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Interest income primarily consists of interest income generated from OnKure’s cash equivalents in interest-bearing money market accounts.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Interest Expense","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Interest Expense","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Interest expense consists of interest expense generated from OnKure’s convertible notes payable.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Results of Operations","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Comparison of the Three Months Ended June 30, 2024 and 2023","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Comparison of the Three Months Ended June 30, 2024 and 2023","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The following table summarizes OnKure’s results of operations for the periods indicated:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Three Months EndedJune 30,","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2024","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2023","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$ Change","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(in thousands)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Operating expenses:","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Research and development","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"10,752","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"7,514","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"3,238","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"General and administrative","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"3,591","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"1,120","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2,471","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Total operating expenses","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"14,343","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"8,634","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"5,709","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Loss from operations","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(14,343","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(8,634","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(5,709","l":8},{"t":"TABLE_CELL","c":")","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Other income (expense), net","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Interest income","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"230","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"451","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(221","l":8},{"t":"TABLE_CELL","c":")","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Interest expense","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(26","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"—","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(26","l":8},{"t":"TABLE_CELL","c":")","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Total other income (expense), net","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"204","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"451","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(247","l":8},{"t":"TABLE_CELL","c":")","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Net loss and comprehensive loss","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(14,139","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(8,183","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(5,956","l":8},{"t":"TABLE_CELL","c":")","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Research and Development Expenses","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Research and Development Expenses","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Research and development expenses were $10.8 million for the three months ended June 30, 2024 compared to $7.5 million for the three months ended June 30, 2023, an increase of $3.2 million. This increase was primarily due to an increase in research and development costs, consisting of a $0.9 million increase in clinical trial and manufacturing expenses and a $2.7 million increase in personnel-related costs due to an increase in headcount, severance and share-based compensation charges. These increases were partially offset by a decrease of $0.5 million in outsourced research.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"General and Administrative Expenses","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"General and Administrative Expenses","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"General and administrative expenses were $3.6 million for the three months ended June 30, 2024 compared to $1.1 million for the three months ended June 30, 2023, an increase of $2.5 million. The increase was primarily due to an increase in personnel-related and consulting costs of $0.6 million and an increase in legal service costs of $1.8 million.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"11","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Other Income (Expense), net","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Other Income (Expense), net","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Other income (expense), net was $0.2 million for the three months ended June 30, 2024 compared to $0.5 million for the three months ended June 30, 2023, a decrease of $0.3 million. The decrease was primarily due to a decrease in cash and cash equivalents available during the quarter ended June 30, 2024.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Comparison of the Six Months Ended June 30, 2024 and 2023","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Comparison of the Six Months Ended June 30, 2024 and 2023","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The following table summarizes OnKure’s results of operations for the periods indicated:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Six Months EndedJune 30,","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2024","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2023","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$ Change","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(in thousands)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Operating expenses:","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Research and development","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"19,318","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"15,037","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"4,281","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"General and administrative","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"4,857","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2,349","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2,508","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Total operating expenses","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"24,175","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"17,386","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"6,789","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Loss from operations","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(24,175","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(17,386","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(6,789","l":8},{"t":"TABLE_CELL","c":")","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Other income (expense), net","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Interest income","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"526","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"524","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Interest expense","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(26","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"—","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(26","l":8},{"t":"TABLE_CELL","c":")","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Total other income (expense), net","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"500","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"524","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(24","l":8},{"t":"TABLE_CELL","c":")","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Net loss and comprehensive loss","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(23,675","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(16,862","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(6,813","l":8},{"t":"TABLE_CELL","c":")","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Research and Development Expenses","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Research and Development Expenses","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Research and development expenses were $19.3 million for the six months ended June 30, 2024 compared to $15.0 million for the six months ended June 30, 2023, an increase of $4.3 million. This increase was primarily due to an increase in research and development costs, consisting of a $1.9 million increase in clinical trial and manufacturing expenses and a $3.5 million increase in personnel-related costs due to an increase in headcount, severance and share-based compensation charges. These increases were partially offset by a decrease of $1.2 million in outsourced research.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"General and Administrative Expenses","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"General and Administrative Expenses","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"General and administrative expenses were $4.9 million for the six months ended June 30, 2024 compared to $2.3 million for the six months ended June 30, 2023, an increase of $2.5 million. The increase was primarily due to an increase in personnel-related and consulting costs of $0.6 million and an increase in legal service costs of $1.8 million.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Other Income (Expense), net","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Other Income (Expense), net","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Other income (expense), net was $0.5 million for each of the six months ended June 30, 2024 and June 30, 2023.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"12","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Comparison of the Years Ended December 31, 2024 and 2023","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Comparison of the Years Ended December 31, 2024 and 2023","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The following table summarizes OnKure’s results of operations for the periods indicated:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Year Ended December 31,","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2023","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2022","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(in thousands)","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Operating expenses:","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Research and development","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"32,115","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"25,862","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"General and administrative","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"4,819","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"3,904","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Total operating expenses","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"36,934","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"29,766","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Loss from operations","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(36,934","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(29,766","l":8},{"t":"TABLE_CELL","c":")","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Other income (expense), net","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Interest income","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"1,623","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"254","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Total other income (expense), net","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"1,623","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"254","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Net loss and comprehensive loss","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(35,311","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(29,512","l":8},{"t":"TABLE_CELL","c":")","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Research and Development Expenses","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Research and Development Expenses","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Research and development expenses were $32.1 million for the year ended December 31, 2023 compared to $25.9 million for the year ended December 31, 2022, an increase of $6.2 million. The increase was primarily due to an increase in manufacturing costs of $3.4 million, an increase in clinical trial costs of $2.0 million, as well as an increase in personnel-related costs of $1.9 million related to an increase in headcount. These increases were partially offset by a decrease in outsourced research costs of $1.3 million.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"General and Administrative Expenses","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"General and Administrative Expenses","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"General and administrative expenses were $4.8 million for the year ended December 31, 2023 compared to $3.9 million for the year ended December 31, 2022, an increase of $0.9 million. The increase was primarily due to an increase of $0.6 million in personnel-related costs and an increase of $0.4 million in legal service costs.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Other Income (Expense), net","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Other Income (Expense), net","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Other income (expense), net was $1.6 million for the year ended December 31, 2023 compared to $0.3 million for the year ended December 31, 2022, an increase of $1.4 million. The increase was primarily due to an increase in cash and cash equivalents available during 2023.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Liquidity and Capital Resources","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Sources of Liquidity","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Sources of Liquidity","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Since inception, OnKure has not generated any revenue from product sales and has incurred significant operating losses and negative cash flows from its operations. OnKure expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances the clinical development of its product candidates. OnKure expects that its research and development and general and administrative costs will continue to increase significantly, including in connection with conducting clinical trials and manufacturing its product candidates to support commercialization and providing general and administrative support for its operations, including the costs associated with operating as a public company following the Closing. As a result, OnKure will need additional capital to fund its operations, which OnKure may seek to obtain from equity or debt financings, collaborations, licensing arrangements or other sources.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"OnKure has funded its operations primarily through private placements of common stock, convertible preferred stock and convertible debt, for cumulative gross proceeds of approximately $122 million as of June 30, 2024. However,","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"13","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"OnKure has incurred significant recurring losses, including net losses of $23.7 million and $35.3 million for the six months ended June 30, 2024 and the year ended December 31, 2023, respectively. OnKure had an accumulated deficit of $125.7 million as of June 30, 2024.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Going Concern","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"As of June 30, 2024, OnKure had cash and cash equivalents of $18.6 million. These factors raised substantial doubt about OnKure’s ability to continue as a going concern prior to the completion of the Merger and the Concurrent PIPE Investments. After giving effect to the completion of the Merger and the Concurrent PIPE Investments, OnKure believes the resulting cash resources will be sufficient to fund its planned for at least the next twelve months.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Future Capital Requirements","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"OnKure’s primary uses of cash to date have been to fund its research and development activities, including with respect to its PI3Kα and other programs, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital and providing general and administrative support for these activities.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"OnKure has never generated any revenue from product sales. Management does not expect to generate any meaningful product revenue unless and until OnKure obtains regulatory approval for its product candidates, and management does not know when, or if, that will occur. Until OnKure can generate significant revenue from product sales, if ever, it will continue to require substantial additional capital to develop its product candidates and fund operations for the foreseeable future. OnKure is subject to all the risks inherent in the development of new biopharmaceutical products, and OnKure may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm its business.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"In order to complete the development of OnKure’s product candidates and to build the sales, marketing and distribution infrastructure that management believes will be necessary to commercialize product candidates, if approved, OnKure will require substantial additional capital. Accordingly, until such time that OnKure can generate a sufficient amount of revenue from product sales or other sources, management expects to seek to raise any necessary additional capital through equity financings, debt financings or other capital sources, which could include income from collaborations, partnerships, licensing or other strategic arrangements with third parties. To the extent that OnKure raises additional capital through equity financings or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of its stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting OnKure’s ability to take specific actions, including restricting its operations and limiting its ability to incur liens, issue additional debt, pay dividends, repurchase its own common stock, make certain investments or engage in merger, consolidation, licensing or asset sale transactions. If OnKure raises capital through collaborations, partnerships and other similar arrangements with third parties, it may be required to grant rights to develop and market product candidates that OnKure would otherwise prefer to develop and market itself. OnKure may be unable to raise additional capital from these sources on favorable terms, or at all.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"OnKure’s ability to secure capital is dependent upon a number of factors, including its success in developing its product candidates. The failure to obtain sufficient capital on acceptable terms when needed could have a material adverse effect on OnKure’s business, results of operations or financial condition, including requiring OnKure to delay, reduce or curtail its research, product development or future commercialization efforts. OnKure may also be required to license rights to product candidates at an earlier stage of development or on less favorable terms than OnKure would otherwise choose. Management cannot provide assurance that OnKure will ever generate positive cash flow from operating activities.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"OnKure’s future funding requirements will depend on many factors, including:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the scope, timing, progress, results and costs of researching and developingOKI-219,and conducting preclinical studies and clinical trials;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the scope, timing, progress, results and costs of researching and developing other product candidates that OnKure may pursue;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"14","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the costs, timing and outcome of regulatory review of OnKure’s product candidates;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution for OnKure’s product candidates for which it receives marketing approval;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the costs of manufacturing commercial-grade products and producing sufficient inventory to support commercial launch;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the revenue, if any, received from commercial sales of OnKure’s products, should its product candidates receive marketing approval;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the cost and timing of attracting, hiring and retaining skilled personnel to support OnKure’s operations and continued growth;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing OnKure’s intellectual property rights and defending intellectual property-related claims;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"OnKure’s ability to establish, maintain and derive value from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties on favorable terms, if at all;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the extent to which OnKure acquires orin-licensesother product candidates and technologies, if any; and","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"the costs associated with operating as a public company.","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"OKI-219","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Cash Flows","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Cash Flows","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The following table summarizes OnKure’s cash flows for the periods indicated, in thousands:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Six Months EndedJune 30,","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Year EndedDecember 31,","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2024","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2023","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2023","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2022","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Net cash used in operating activities","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(17,102","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(15,646","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(34,546","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(26,953","l":8},{"t":"TABLE_CELL","c":")","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Net cash used in investing activities","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(19","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(71","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(246","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"(1,134","l":8},{"t":"TABLE_CELL","c":")","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Net cash provided by financing activities","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"5,878","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"53,106","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"53,125","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"26,465","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Net increase (decrease) in cash and cash equivalents","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(11,243","l":8},{"t":"TABLE_CELL","c":")","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"37,389","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"18,333","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"(1,622","l":8},{"t":"TABLE_CELL","c":")","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Cash Flows from Operating Activities","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Cash Flows from Operating Activities","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"by non-cash charges","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Net cash used in operating activities during the six months ended June 30, 2023 was $15.6 million. This consisted primarily of a net loss of $16.9 million, partially offset by a net increase in OnKure’s operating assets and liabilities of $0.9 million, primarily due to increases in accounts payable and accrued expenses.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"the non-cash charge","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Net cash used in operating activities during the year ended December 31, 2022 was $27.0 million. This consisted primarily of a net loss of $29.5 million, partially offset by a net increase in OnKure’s operating assets and liabilities of $2.1 million, primarily due to increases in accounts payable and accrued expenses.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Cash Flows from Investing Activities","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Cash Flows from Investing Activities","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Net cash used in investing activities for the six months ended June 30, 2024 was $19 thousand and related to purchase of property and equipment.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"15","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Net cash used in investing activities for the three months ended June 30, 2023 was $71 thousand and related to purchase of property and equipment.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Net cash used in investing activities for the year ended December 31, 2023 was $0.2 million and related to purchase of property and equipment.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Net cash used in investing activities for the year ended December 31, 2022 was $1.1 million and related to leasehold improvements and the purchase of property and equipment.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Cash Flows from Financing Activities","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Cash Flows from Financing Activities","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Net cash provided by financing activities was $5.9 million during the six months ended June 30, 2024 and related primarily to proceeds from the issuance of convertible notes payable.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Net cash provided by financing activities was $53.1 million during the six months ended June 30, 2023. This consisted primarily of proceeds of $53.8 million resulting from the sale of shares of OnKure preferred stock, partially offset by $0.7 million of issuance costs.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Net cash provided by financing activities during the year ended December 31, 2023 was $53.1 million. This consisted primarily of proceeds of $53.8 million resulting from the sale of shares of OnKure preferred stock, partially offset by $0.7 million of issuance costs.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Net cash provided by financing activities during the year ended December 31, 2022 was $26.5 million. This consisted primarily of proceeds of $27.5 million resulting from the sale of shares of OnKure preferred stock and $0.3 million related to proceeds from the sale of shares of OnKure common stock, partially offset by $1.4 million of issuance costs.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Contractual Obligations and Commitments","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Contractual Obligations and Commitments","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"OnKure leases certain office space in Boulder, Colorado pursuant to a lease which is scheduled to expire on December 31, 2026.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The following table summarizes OnKure’s contractual obligations and commitments as of June 30, 2024 (in thousands):","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Payments Due by Period","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Total","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Remainderof 2024","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2025-2026","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Thereafter","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Operating lease obligation","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"605","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"118","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"487","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"$","l":8},{"t":"TABLE_CELL","c":"—","l":8},{"t":"TABLE_CELL","c":"","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"OnKure also entered into agreements in the normal course of business with certain vendors for the provision of goods and services, which includes manufacturing services with CMOs and development services with CROs. These agreements may include certain provisions for purchase obligations and termination obligations that could require payments for the cancellation of committed purchase obligations or for early termination of the agreements. The amounts of the cancellation or termination payments vary and are based on the timing of the cancellation or termination and the specific terms of the agreement. These obligations and commitments are not separately presented.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Off-Balance","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"any off-balance sheet","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Critical Accounting Policies and Significant Judgments and Estimates","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"OnKure’s financial statements are prepared in accordance with U.S. GAAP. The preparation of OnKure’s financial statements and related disclosures requires OnKure to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in its","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"16","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"financial statements. OnKure bases its estimates on historical experience, known trends and events and various other factors that OnKure believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. OnKure evaluates its estimates and assumptions on a periodic basis. OnKure’s actual results may differ from these estimates.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K,","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"There have been no material changes to OnKure’s significant accounting policies during the period ended June 30, 2024.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Accrued Research and Development Expense","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Accrued Research and Development Expense","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"OnKure records research and development expenses in the period in which it receives or takes ownership of the applicable goods or when the applicable services are performed. OnKure is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants and CROs in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. OnKure reflects research and development expenses in its financial statements by matching those expenses with the period in which services are expended. OnKure accounts for these expenses according to the progress of the preclinical studies or clinical trials, as measured by the timing of various aspects of the study or related activities. OnKure determines accrual estimates through a review of the underlying contracts along with the preparation of financial models considering discussions with research and other key personnel as to the progress of studies, trials or other services being conducted. During a study or trial, OnKure adjusts its rate of expense recognition if actual results differ from its estimate. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as an expense in the period that the related goods are consumed, or services are performed.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Share-Based Compensation","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Share-Based Compensation","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"zero-coupon","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"17","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Legacy OnKure Common Stock Valuation","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Legacy OnKure Common Stock Valuation","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"per-share","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Each valuation methodology includes estimates and assumptions that require management’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which Legacy OnKure sold shares of Legacy OnKure preferred stock, the superior rights and preferences of the Legacy OnKure preferred stock senior to Legacy OnKure common stock at the time, the progress of Legacy OnKure’s research and development programs, including their stages of development, Legacy OnKure’s business strategy, trends within the biotechnology industry, Legacy OnKure’s financial position, including cash on hand and its historical and forecasted performance and operating results, the lack of an active public market for Legacy OnKure common stock, the market performance of peer companies in the biopharmaceutical industry, and a probability analysis of various liquidity events, such as a public offering or sale of Legacy OnKure, under differing scenarios. Changes to the key assumptions used in the valuations could result in materially different fair values of Legacy OnKure common stock at each valuation date.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Following the closing of the Merger, the Board will determine the fair value of Class A Common Stock based on the closing price of the Class A Common Stock as reported on the date of grant on the primary stock exchange on which such common stock is traded.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Legacy OnKure recorded share-based compensation expense of $1.8 million and $17 thousand for the three months ended June 30, 2024 and 2023, respectively, $1.9 million and $32 thousand for the six months ended June 30, 2024 and 2023, respectively, and $0.2 million and $48 thousand for the years ended December 31, 2023 and 2022, respectively. Legacy OnKure recorded accelerated share-based compensation expenses related to modifications of RSUs under certain separation agreements of $1.7 million during the three and six months ended June 30, 2024. As of June 30, 2024, Legacy OnKure had $0.4 million of unrecognized share-based compensation expense for unvested stock options, which it expects to recognize over an estimated weighted-average period of 2.6 years. As of June 30, 2024, Legacy OnKure had $0.3 million of unrecognized share-based compensation expense for unvested restricted stock unit awards, which it expects to recognize over an estimated weighted-average period of 2.7 years. OnKure expects to continue to grant stock options and other share-based awards in the future, and to the extent that it does, OnKure’s share-based compensation expense recognized in future periods will likely increase.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Recent Accounting Pronouncements","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K.","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Quantitative and Qualitative Disclosures About Market Risks","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Interest Rate Risk","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Interest Rate Risk","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"As of June 30, 2024 and December 31, 2023, OnKure’s cash and cash equivalents consisted primarily of U.S. Treasury-backed money market funds. OnKure’s primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the short-term maturities of OnKure’s investments, OnKure believes a hypothetical 100 basis point increase or decrease in interest rates during any of the periods presented would not have had a material impact on its financial results.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"18","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"As of June 30, 2024, OnKure had convertible notes payable outstanding with fixed interest rates and was therefore not exposed to interest rate risk with respect to debt.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Foreign Currency Exchange Risk","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Foreign Currency Exchange Risk","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"OnKure’s primary operations are transacted in U.S. dollars. However, OnKure has entered into a limited number of contracts with vendors for research and development services that are denominated in foreign currencies, including the British Pound or Euros. OnKure could be subject to foreign currency transaction gains or losses on OnKure’s contracts denominated in foreign currencies. OnKure does not currently engage in any hedging activity to reduce OnKure’s potential exposure to currency fluctuations, although it may choose to do so in the future. OnKure believes a hypothetical 100 basis point increase or decrease in foreign exchange rates during any of the periods presented would not have had a material impact on its financial condition or results of operations.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Security Ownership of Certain Beneficial Owners and Management","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The following table sets forth certain information regarding beneficial ownership of the shares of Class A Common Stock immediately after completion of the Merger and the Concurrent PIPE Investments, by:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"each person known by the Combined Company to be the beneficial owner of more than 5% of the Combined Company’s outstanding Class A Common Stock immediately following the consummation of the Transactions;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"each of the Combined Company’s executive officers and directors; and","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"all of the Combined Company’s directors and executive officers as a group.","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if such person possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities that such person has the right to acquire, such as through the exercise of stock options, within 60 days of the Closing Date. Shares subject to warrants and options that are currently exercisable or exercisable within 60 days of the Closing Date are considered outstanding and beneficially owned by the person holding such warrant and/or options for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-voting","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"19","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Name of Beneficial Owner","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Number ofShares ofClass ACommonStockBeneficiallyOwned","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Percentage ofShares ofClass ACommonStockOutstandingBeneficiallyOwned","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Greater than 5% Stockholders:","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Acorn Bioventures, L.P. (1)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"1,439,674","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"11.4","l":8},{"t":"TABLE_CELL","c":"%","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Entities affiliated with Citadel Advisors (2)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"1,062,836","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"8.4","l":8},{"t":"TABLE_CELL","c":"%","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Entities affiliated with Cormorant Asset Management LP (3)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"1,837,739","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"14.5","l":8},{"t":"TABLE_CELL","c":"%","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Perceptive Life Sciences Master Fund, Ltd. (4)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"1,004,439","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"7.9","l":8},{"t":"TABLE_CELL","c":"%","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Samsara BioCapital, L.P. (5)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"824,155","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"6.5","l":8},{"t":"TABLE_CELL","c":"%","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Named Executive Officers and Directors:","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Nicholas A. Saccomano, Ph.D. (6)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"—","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"—","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Jason Leverone, CPA (7)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"—","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"—","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Isaac Manke, Ph.D. (1)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"1,439,674","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"11.4","l":8},{"t":"TABLE_CELL","c":"%","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"R. Michael Carruthers (8)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"874","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"*","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Andrew Phillips, Ph.D.","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"—","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"—","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Michael Grey (9)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"87,821","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"*","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Edward T. Mathers (10)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"4,900","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"*","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Valerie M. Jansen","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"—","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"—","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"All directors and executive officers as a group (eight persons)","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"1,533,269","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"12.1","l":8},{"t":"TABLE_CELL","c":"%","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"*","l":8},{"t":"TABLE_CELL","c":"Represents beneficial ownership of less than 1%.","l":8}]}]}]},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"(1)","l":8},{"t":"TABLE_CELL","c":"Consists of (i) 1,240,485 shares of Class A Common Stock received in the Merger, and (ii) 199,189 shares of Class A Common Stock purchased in the Concurrent PIPE Investments. Acorn Capital Advisors, GP, LLC (“Acorn GP” is the general partner of Acorn Bioventures L.P. Acorn GP has discretionary authority to vote and dispose of the shares held by Acorn Bioventures L.P. and, accordingly, Acorn GP may be deemed to have beneficial ownership of such shares. Anders Hove is the manager of Acorn GP and, in his capacity as such, may be deemed to beneficially own the shares held by Acorn Bioventures L.P. Dr. Isaac Manke, a member of the Board, is a partner at Acorn GP. Each of Acorn GP, Dr. Hove and Dr. Manke disclaim beneficial ownership of the shares held by Acorn Bioventures L.P., except to the extent of their respective pecuniary interests therein. The business address for these persons is 420 Lexington Avenue, Suite 2626, New York, NY 10170.","l":8}]}]}]},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"(2)","l":8},{"t":"TABLE_CELL","c":"Consists of (i) 702,044 shares of Class A Common Stock received in the Merger and held by Citadel Multi-Strategy Equities Master Fund Ltd. (“CM”) and (ii) 360,792 shares of Class A Common Stock purchased by Citadel CEMF Investments Ltd. (“CEMF Investments”) in the Concurrent PIPE Investments. Does not include 686,527 shares of Class A Common Stock otherwise issuable to CM in the Merger that were issued instead as Class B Common Stock. The Class B Common Stock isnon-votingand is convertible into the Class A Common Stock subject to a customary 9.9% beneficial ownership blocker. As a result, including the portion of the shares of Class B Common Stock that would be convertible into Class A Common Stock immediately following the Transactions would increase the beneficial ownership of CM and its affiliates to 9.9% of the shares of Class A Common Stock outstanding. Citadel Advisors LLC (“Citadel Advisors”) is the portfolio manager of CM and CEMF Investments. Citadel Advisors Holdings LP (“CAH”) is the sole member of Citadel Advisors. Citadel GP LLC (“CGP”) is the general partner of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr. Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote or direct the vote of, and/or shared power to dispose or to direct the disposition of, the shares held by CEMF. This response is not and shall not be construed as an admission that Mr. Griffin or any of the Citadel related entities listed above is the beneficial owner of any securities of the Combined Company other than the securities actually owned by such person (if any). The address for each of these persons is c/o Citadel Enterprise Americas, Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, FL 33131.","l":8}]}]}]},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"(3)","l":8},{"t":"TABLE_CELL","c":"Consists of (i) 105,845 shares of Class A Common Stock received in the Merger and held by Cormorant Global Healthcare Master Fund, LP (“Master Fund”) and 329,089 shares of Class A Common Stock Purchased in the Concurrent PIPE Investments; (ii) 1,109,451 shares of Class A Common Stock received in the Merger and held","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"20","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"by Cormorant Private Healthcare Fund III, LP (“Fund III”); (iii) 235,480 shares of Class A Common Stock received in the Merger and held by Cormorant Private Healthcare Fund IV, LP (“Fund IV”); (iv) 7,945 shares of Class A Common Stock received in the Merger and held by CRMA SPV, LP (“CRMA”); (v) 49,929 shares of Class A Common Stock purchased by Cormorant Global Healthcare Fund V, LP (“Fund V”) in the Concurrent PIPE Investments. Cormorant Global Healthcare GP, LLC serves as the general partner of Master Fund, Cormorant Private Healthcare GP III, LLC serves as the general partner of Fund III, Cormorant Private Healthcare GP IV, LLC serves as the general partner of Fund IV, Cormorant Private Healthcare GP V, LLC serves as the general partner of Fund V, and Cormorant Asset Management, LP (“Cormorant”) serves as the investment manager to Master Fund, Fund III, Fund IV, Fund V and CRMA. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant and therefore may be deemed to share voting and investment power over such shares. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein. The address for each of reporting person is 200 Clarendon Street 52nd Floor, Boston, Massachusetts 02116.","l":8}]}]}]},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"(4)","l":8},{"t":"TABLE_CELL","c":"Consists of (i) 797,282 shares of Class A Common Stock received in the Merger, and (ii) 207,157 shares of Class A Common Stock purchased by in the Concurrent PIPE Investments. Perceptive Advisors LLC (the “Advisor”) serves as the investment manager to Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”). Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of the shares held by the Master Fund, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities. The address for Perceptive Life Sciences Master Fund, Ltd. and Perceptive Advisors LLC is 51 Astor Place, 10th Floor, New York, NY 10003.","l":8}]}]}]},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"(5)","l":8},{"t":"TABLE_CELL","c":"Consists of (i) 654,180 shares of Class A Common Stock received in the Merger, and (ii) 169,975 shares of Class A Common Stock purchased in the Concurrent PIPE Investments. Samsara BioCapital GP, LLC is the general partner of by Samsara BioCapital, L.P. (“Samsara LP”) and therefore may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein. The address for Samsara LP is 628 Middlefield Road, Palo Alto, CA 94301.","l":8}]}]}]},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"(6)","l":8},{"t":"TABLE_CELL","c":"Consists of shares of Class A Common Stock subject to options held by Dr. Saccomano exercisable within 60 days of the Closing Date.","l":8}]}]}]},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"(7)","l":8},{"t":"TABLE_CELL","c":"Consists of shares of Class A Common Stock subject to options held by Mr. Leverone exercisable within 60 days of the Closing Date.","l":8}]}]}]},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"(8)","l":8},{"t":"TABLE_CELL","c":"Consists of shares of Class A Common Stock subject to options held by Mr. Carruthers exercisable within 60 days of the Closing Date.","l":8}]}]}]},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"(9)","l":8},{"t":"TABLE_CELL","c":"Consists of (i) 49,476 shares of Class A Common Stock held by The Grey Family Trust dated November 12, 1999 (the Grey 1999 Trust), (ii) 13,408 shares of Class A Common Stock held by Michael Grey and Rondi Rauch Grey,Co-Trusteesof The Grey 2014 Irrevocable Children’s Trust u/a/d 12/17/14 (the Grey 2014 Trust), and (iii) 24,937 shares of Class A Common Stock subject to options held by Mr. Grey exercisable within 60 days of the Closing Date. Mr. Grey, Reneo’s former Executive Chairman and a member of the Board of the Combined Company, is trustee of each of the Grey 1999 Trust and Grey 2014 Trust, and in such capacity has the power to vote and dispose of such shares held by the Grey 1999 Trust and Grey 2014 Trust.","l":8}]}]}]},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"(10)","l":8},{"t":"TABLE_CELL","c":"Consists of shares of Class A Common Stock subject to options held by Mr. Mathers exercisable within 60 days of the Closing Date.","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Directors and Executive Officers","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Directors and Executive Officers","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The Combined Company’s directors and executive officers after the consummation of the Transactions are described in the Proxy Statement/Prospectus in the section titled “Management Following the Proposed Transactions” beginning on page 267 of the Proxy Statement/Prospectus and that information is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Independence of our Board of Directors","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Independence of our Board of Directors","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Under the Nasdaq listing standards, a majority of the members of the Combined Company Board must qualify as “independent,” as affirmatively determined by the Combined Company Board. Under the rules of Nasdaq, a director will only qualify as an “independent director” if, in the opinion of that company’s board of directors, that person does","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"21","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The Combined Company Board has determined that each individual serving on the Combined Company Board upon consummation of the Merger other than Nicholas Saccomano and Michael Grey qualifies as an independent director under Nasdaq listing standards.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Committees of the Board of Directors","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Committees of the Board of Directors","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Committees of the NewCo Board","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Executive Compensation","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Executive Compensation","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Form 10-K","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"At the Special Meeting, the Reneo stockholders approved the 2024 Plan and the 2024 ESPP. The summary of the 2024 Plan set forth in the Proxy Statement/Prospectus in the subsection titled “Proposal No. 5 - Approval of the 2024 Equity Incentive Plan” in the section titled “Matters Being Submitted to a Vote of Reneo Stockholders” beginning on page 203 of the Proxy Statement/Prospectus and the summary of the 2024 ESPP set forth in the Proxy Statement/Prospectus in the subsection titled “Proposal No. 6 - Approval of the 2024 ESPP” in the section titled “Matters Being Submitted to a Vote of Reneo Stockholders” beginning on page 215 of the Proxy Statement/Prospectus are each incorporated herein by reference. A copy of the full text of the 2024 Plan is attached hereto as Exhibit 10.14 and a copy of the full text of the 2024 ESPP is attached hereto as Exhibit 10.15, each of which is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Director Compensation","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Director Compensation","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Compensation—Non-Employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Form 10-K","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Certain Relationships and Related Person Transactions","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Certain Relationships and Related Person Transactions","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Certain relationships and related person transactions are described in the Proxy Statement/Prospectus in the section titled “Related Party Transactions of the Combined Company,” beginning on page 293 of the Proxy Statement/Prospectus and that information is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Legal Proceedings","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Legal Proceedings","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Kyle Thomas v. Reneo Pharmaceuticals, Inc., Michael Grey, Roshawn Blunt, Eric Dube, Gregory J. Flesher, Paul W. Hoelscher, Ed Mathers, Bali Muralidhar, Niall O’Donnell, and Stacy Seltzer,","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Michael Kent v. Reneo Pharmaceuticals, Inc., Michael Grey, Roshawn Blunt, Eric Dube, Gregory J. Flesher, Paul W. Hoelscher, Ed Mathers, Bali Muralidhar, Niall O’Donnell, and Stacy Seltzer,","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Complaints","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Complaints","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"22","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Partners, Reneo’s financial advisor, and potential conflicts of interest with Leerink Partners LLC, Evercore Group L.L.C., and LifeSci Capital LLC, which are the placement agents for the Concurrent PIPE Investments. The Complaints assert violations of negligent misrepresentation and concealment in violation of New York common law and negligence in violation of New York common law. The Complaints seek orders enjoining the proposed Merger, or in the event that the proposed Merger is consummated, orders rescinding the Merger or awarding actual and punitive damages, as well as all of the plaintiffs’ fees and expenses in connection with the litigation, including reasonable attorneys’ and experts’ fees and expenses.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Demands","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Demands","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"We cannot predict the outcome of any litigation or the Demands. The Combined Company and the individual defendants intend to vigorously defend against the allegations made in the Complaints, the Demands, and any subsequently filed similar actions. It is possible additional lawsuits may be filed or additional demand letters may be received arising out of the Merger.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Supplemental Disclosures","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Supplemental Disclosures","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Market Price of and Dividends on Common Equity and Related Stockholder Matters","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Market Price of and Dividends on Common Equity and Related Stockholder Matters","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The Class A Common Stock began trading on Nasdaq under the symbol “OKUR” on October 7, 2024. As of immediately after the Closing Date, there were approximately 96 registered holders of Common Stock. Any decision to declare and pay dividends in the future will be made at the sole discretion of the Board and will depend on, among other things, the Combined Company’s results of operations, cash requirements, financial condition, contractual restrictions and other factors that the Board may deem relevant.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Recent Sales of Unregistered Securities","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Recent Sales of Unregistered Securities","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Description of Company’s Securities","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Description of Company’s Securities","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The description of the Company’s securities is contained in the Proxy Statement/Prospectus in the section titled “Description of Capital Stock of NewCo” beginning on page 312 of the Proxy Statement/Prospectus and that information is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Indemnification of Officers and Directors","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Indemnification of Officers and Directors","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The Combined Company has entered into indemnification agreements with each of its directors and executive officers, in each case effective as of the Closing Date. Each indemnification agreement provides for indemnification and advancements by the Combined Company of certain expenses and costs relating to claims, suits or proceedings arising from such person’s service to the Combined Company or, at our request, service to other entities, as officers or directors to the maximum extent permitted by applicable law.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Financial Statements and Exhibits","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Financial Statements and Exhibits","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"23","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item 3.02. Unregistered Sales of Equity Securities","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"PIPE Shares","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"PIPE Shares","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Securities Act","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Securities Act","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Resale Registration Statement","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Resale Registration Statement","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item 3.03. Material Modifications to Rights of Security Holders.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"At the Special Meeting, the Reneo stockholders approved an amendment to the amended and restated certificate of incorporation of the Company to, among other things, effect the Reverse Stock Split of the Common Stock at a ratio of 1:10. On October 4, 2024, in connection with the Merger and effective immediately prior to the Effective Time, the Company filed a certificate of amendment to the amended and restated certificate of incorporation to effect the Reverse Stock Split and immediately thereafter filed an amended and restated certificate of incorporation to change the name of the Company from Reneo Pharmaceuticals, Inc. to OnKure Therapeutics, Inc., create the Class B Common Stock and reclassify the Reneo common stock as Class A Common Stock, among other things. As of the opening of trading on Nasdaq on October 7, 2024, the Class A Common Stock began to trade on a Reverse Stock Split-adjusted basis (as well as under the new ticker symbol “OKUR”).","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"As a result of the Reverse Stock Split, the number of issued and outstanding shares of Reneo common stock immediately prior to the Reverse Stock Split was reduced into a smaller number of shares, such that every 10 shares of Reneo common stock held by a stockholder immediately prior to the Reverse Stock Split were combined and reclassified into one share of Class A Common Stock after the Reverse Stock Split. Immediately following the Reverse Stock Split, the Merger and the Concurrent PIPE Investments, there were approximately 12,652,811 million shares of Class A Common Stock and 686,527 shares of Class B Common Stock outstanding.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"pre-split","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"pre-split","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"In accordance with the amended and restated certificate of incorporation of the Company, as amended, no corresponding adjustment was made with respect to the Company’s authorized Common Stock or preferred stock. The Reverse Stock Split has no effect on the par value of the Common Stock or preferred stock of the Company. Immediately after the Reverse Stock Split, prior to giving effect to the Merger, each stockholder’s percentage ownership interest in the Company and proportional voting power remained unchanged, other than as a result of the rounding to eliminate fractional shares, as described in the preceding paragraph. The rights and privileges of the holders of shares of Common Stock will be unaffected by the Reverse Stock Split.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The foregoing description of the certificate of amendment to the amended and restated certificate of incorporation of the Company to effect the Reverse Stock Split is not complete and is subject to and qualified in its entirety by reference to the certificate of amendment to the amended and restated certificate of incorporation, a copy of which is attached as Exhibit 3.1 hereto and is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"24","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"12g-3(a)","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Exchange Act","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Exchange Act","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item 5.01. Changes in Control of Registrant.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K,","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Board of Directors","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Board of Directors","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Upon the consummation of the Transactions, and in accordance with the terms of the Merger Agreement, each director of Reneo, other than Michael Grey and Edward T. Mathers, ceased serving in such capacity and five new directors were appointed to the Board. In accordance with the amended and restated certificate of incorporation of the Company, the Board is divided into three staggered classes of directors and each director was assigned to one of the three classes. At each annual meeting of the stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the year 2025 for Class I directors, 2026 for Class II directors, and 2027 for Class III directors. Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Furthermore, also on October 4, 2024, the Board confirmed that there would continue to be three standing committees of the Board: an audit committee, a compensation committee and a nominating and corporate governance committee. The Board appointed the following members to the audit committee: R. Michael Carruthers, Andrew Phillips and Isaac Manke, with R. Michael Carruthers appointed as the chairperson of the audit committee. The Board appointed the following members to the compensation committee: Andrew Phillips, Isaac Manke, and Edward T. Mathers, with Andrew Phillips appointed as the chairperson of the compensation committee. The Board appointed the following members to the nominating and corporate governance committee: Isaac Manke and Valerie M. Jansen, with Isaac Manke appointed as the chairperson of the nominating and corporate governance committee.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Also on October 4, 2024, Andrew Phillips, Ph.D. was appointed as the Chair of the Board.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Compensation—Non-Employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Form 10-K","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"25","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Outside Director Compensation Policy","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Outside Director Compensation Policy","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Retainer Award","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Retainer Award","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Closing Award","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Closing Award","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"thirty-six","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Initial Award","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Initial Award","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"S-8","l":7}]},{"t":"CONTAINER","c":"sup","l":6,"ch":[{"t":"SECTION_TITLE","c":"th","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Annual Meeting","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Annual Meeting","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Annual Award","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Annual Award","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"12-month","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"one-year","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"26","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The foregoing description of the Outside Director Compensation Policy is not complete and is subject to and qualified in its entirety by reference to the Outside Director Compensation Policy, a copy of which is attached as Exhibit 10.21 hereto and is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Executive Officers","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Executive Officers","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Upon the consummation of the Transactions, and in accordance with the terms of the Merger Agreement, each executive officer and Section 16 officer of Reneo (including the principal executive officer, principal financial officer and principal accounting officer) ceased serving in such capacities. On October 4, 2024, the following individuals were appointed to serve as executive officers of the Combined Company:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Name","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Position","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Nicholas Saccomano, Ph.D.","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"President and Chief Executive Officer(Principal Executive Officer)","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Jason Leverone, C.P.A.","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Chief Financial Officer(Principal Financial and Accounting Officer)","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Samuel Agresta, M.D.","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Chief Medical Officer","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"Dylan Hartley, Ph.D.","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Chief Scientific Officer","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Reference is made to the disclosure described in the Proxy Statement/Prospectus in the subsection titled “Management Following the Proposed Transactions” in the section titled “The Mergers” beginning on page 267 of the Proxy Statement/Prospectus, which is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"S-K.","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"2024 Equity Incentive Plan","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"2024 Equity Incentive Plan","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"non-employee","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Reneo 2021 Plan","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Reneo 2021 Plan","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"27","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"evergreen feature, on the first day of each fiscal year, beginning with the Combined Company’s 2025 fiscal year, equal to the least of:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"2,407,100 shares of Class A Common Stock;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"a number of shares of Class A Common Stock equal to 5% of the outstanding shares of all classes of Common Stock as of the last day of the immediately preceding fiscal year;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"or such number of shares of Class A Common Stock as the administrator of the 2024 Plan (or, the Board or its designated committee) may determine no later than the last day of the Combined Company’s immediately preceding fiscal year.","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Shares issuable under the 2024 Plan may be authorized, but unissued, or reacquired shares of Class A Common Stock. If an award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant to an exchange program (as described below), or, with respect to restricted stock, restricted stock units, or performance awards, is forfeited to or repurchased due to failure to vest, the unpurchased shares (or for awards other than stock options or stock appreciation rights, the forfeited or repurchased shares) will become available for future grant or sale under the 2024 Plan. With respect to stock appreciation rights, only the net shares actually issued will cease to be available under the 2024 Plan and all remaining shares under stock appreciation rights will remain available for future grant or sale under the 2024 Plan. Shares that actually have been issued under the 2024 Plan under any award will not be returned to the 2024 Plan; except if shares issued pursuant to awards of restricted stock, restricted stock units, or performance awards are repurchased or forfeited due to failure to vest, such shares will become available for future grant under the 2024 Plan. Shares otherwise issuable under an award that are used to pay the exercise price of an award or satisfy the tax liabilities or withholding obligations related to an award (which withholdings may be in amounts greater than the minimum statutory amount required to be withheld as determined by the administrator of the 2024 Plan) will become available for future grant or sale under the 2024 Plan. To the extent an award is paid out in cash rather than shares, such cash payment will not result in a reduction in the number of shares available for issuance under the 2024 Plan.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"split-up,","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"spin-off,","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"A more complete summary of the terms of the 2024 Plan is set forth in the Proxy Statement/Prospectus in the subsection titled “Proposal No. 5: Approval of the 2024 Equity Incentive Plan” in the section titled “Matters Being Submitted to a Vote of Reneo Stockholders” beginning on page 203 of the Proxy Statement/Prospectus. That summary and the foregoing description of the 2024 Plan does not purport to be complete and is qualified in its entirety by reference to the text of the 2024 Plan, which is attached as Exhibit 10.14 hereto and incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"2024 Employee Stock Purchase Plan","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"2024 Employee Stock Purchase Plan","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"At the Special Meeting of Reneo stockholders held on September 26, 2024, Reneo stockholders considered and approved the 2024 Employee Stock Purchase Plan. Subject to adjustment upon changes in the Combined Company’s capitalization, an aggregate of 137,500 shares of Class A Common Stock are currently reserved and available for issuance under the 2024 ESPP. The number of shares of Class A Common Stock available for issuance under the 2024 ESPP will be increased on the first day of each fiscal year beginning with the 2025 fiscal year, in an amount equal to the least of (a) 481,500 shares of Class A Common Stock, (b) a number of shares of Class A Common Stock equal to 1% of the outstanding shares of Common Stock of the Combined Company on the last day of the immediately preceding fiscal year, or (c) an amount determined by the administrator of the 2024 ESPP (or, the Board or its designated committee). Shares issuable under the 2024 ESPP will be authorized, but unissued, or reacquired shares of Class A Common Stock. If our capital structure changes because of a stock dividend, stock split or similar event, the number of shares that can be issued under the 2024 ESPP, the purchase price per share and the class of and number of shares subject to options under the 2024 ESPP will be appropriately adjusted.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"28","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"A more complete summary of the terms of the 2024 ESPP is set forth in the Proxy Statement/Prospectus in the subsection titled “Proposal No. 6 - Approval of the 2024 ESPP” in the section titled “Matters Being Submitted to a Vote of Reneo Stockholders” beginning on page 215 of the Proxy Statement/Prospectus. That summary and the foregoing description of the 2024 ESPP does not purport to be complete and is qualified in its entirety by reference to the text of the 2024 ESPP, which is attached as Exhibit 10.15 hereto and incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"New OnKure Employment Agreements","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"New OnKure Employment Agreements","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"New Employment Agreements","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"New Employment Agreements","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"one-year","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"CIC Period","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"CIC Period","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"A lump sum cash payment equal to 100% of the executive officer’s base salary as in effect immediately before such termination; and","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Combined Company payment of the premiums required for continued coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) under the Combined Company’s group health, dental and vision care plans for the executive officer and his eligible dependents for up to 12 months.","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"If, during the CIC Period, the applicable executive officer’s employment with the Combined Company is terminated either (x) by the Combined Company without cause (and excluding by reason of his death or disability) or (y) by the executive officer for good reason, the executive officer will receive the following severance payments and benefits if he timely executes and does not revoke a separation agreement and release of claims in the Combined Company’s favor:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"A lump sum cash payment equal to 100% (or 150% for Dr. Saccomano) of the executive officer’s base salary as in effect immediately before such termination, or if greater, the base salary in effect immediately before the change in control;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"A lump sum cash payment equal to 100% (or 150% for Dr. Saccomano) of the executive officer’s target bonus opportunity as in effect immediately before such termination or if greater, the target bonus opportunity in effect immediately before the change in control;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Combined Company payment of the premiums required for continued coverage pursuant to COBRA under the Combined Company’s group health, dental and vision care plans for the executive officer and his eligible dependents for up to 12 months (or 18 months for Dr. Saccomano); and","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"100% accelerated vesting and exercisability of the outstanding and unvested equity awards (other than equity awards subject to performance-based vesting criteria) granted to the executive officer.","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"29","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"after-tax","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"gross-ups","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Form 10-K","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Equity Awards Granted to Executive Officers on the Closing Date","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Equity Awards Granted to Executive Officers on the Closing Date","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"sup","l":6,"ch":[{"t":"SECTION_TITLE","c":"th","l":7}]},{"t":"CONTAINER","c":"sup","l":6,"ch":[{"t":"SECTION_TITLE","c":"th","l":7}]},{"t":"CONTAINER","c":"sup","l":6,"ch":[{"t":"SECTION_TITLE","c":"th","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Executive Incentive Compensation Plan","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Executive Incentive Compensation Plan","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Incentive Compensation Plan","l":7},{"t":"CONTAINER","c":"span","l":7,"ch":[{"t":"SECTION_TITLE","c":"Incentive Compensation Plan","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Under the Incentive Compensation Plan, the administrator determines the performance goals applicable to any award, which goals may include, without limitation, goals related to: attainment of research and development milestones; sales bookings; business divestitures and acquisitions; capital raising; cash flow; cash position; contract awards or backlog; corporate transactions; customer renewals; customer retention rates from an acquired company, subsidiary, business unit or division; earnings (which may include any calculation of earnings, including but not limited to earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation and amortization and net taxes); earnings per share; expenses; financial milestones; gross margin; growth in stockholder value relative to the moving average of the S&P 500 Index or another index; internal rate of return; leadership development or succession planning; license or research collaboration arrangements; market share; net income; net profit; net sales; new product or business development; new product invention or innovation; number of customers; operating cash flow; operating expenses; operating income; operating margin; overhead or other expense reduction; patents; procurement; product defect measures; product release timelines; productivity; profit; regulatory milestones or regulatory-related goals; retained earnings; return on assets; return on capital; return on equity; return on investment; return on sales; revenue; revenue growth; sales results; sales growth; savings; stock price; time to market; total stockholder return; working capital; unadjusted or adjusted actual contract value; unadjusted or adjusted total contract value; and individual objectives such as peer reviews or other subjective or objective criteria. The performance goals may differ from participant to participant and from award to award.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"30","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The administrator of the Incentive Compensation Plan may, in its sole discretion and at any time, increase, reduce or eliminate a participant’s actual award, and/or increase, reduce or eliminate the amount allocated to the bonus pool for a particular performance period. The actual award may be below, at or above a participant’s target award, in the discretion of the administrator. The administrator may determine the amount of any increase, reduction or elimination on the basis of such factors as it deems relevant, and it is not required to establish any allocation or weighting with respect to the factors it considers.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Actual awards will be paid in cash (or its equivalent) in a single lump sum only after they are earned, which usually requires continued employment through the date the actual award is paid. The administrator reserves the right to settle an actual award with a grant of an equity award under the Combined Company’s then-current equity compensation plan, which equity award may have such terms and conditions, as the administrator determines. Payment of awards occurs as soon as administratively practicable after they are earned, but no later than the dates set forth in the Incentive Compensation Plan. The administrator has the authority to amend, alter, suspend or terminate the Incentive Compensation Plan, provided such action does not materially alter or materially impair the existing rights of any participant with respect to any earned awards.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The foregoing description of the Incentive Compensation Plan does not purport to be complete and is qualified in its entirety by the terms and conditions thereof, a copy of which is attached hereto as Exhibit 10.19 and is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Indemnification Agreements","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Indemnification Agreements","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The Combined Company has entered into indemnification agreements with each of its directors and executive officers. Each indemnification agreement provides for indemnification and advancements by the Combined Company of certain expenses and costs relating to claims, suits or proceedings arising from his or her service to the Combined Company or, at our request, service to other entities, as officers or directors to the maximum extent permitted by applicable law.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The foregoing description of the indemnification agreements does not purport to be complete and is qualified in its entirety by the terms and conditions thereof, a form of which is filed herewith as Exhibit 10.22 and is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Certain Relationships and Related Person Transactions","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Certain Relationships and Related Person Transactions","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Certain relationships and related person transactions are described in the Proxy Statement/Prospectus in the section titled “Related Party Transactions of the Combined Company,” beginning on page 293 of the Proxy Statement/Prospectus and that information is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Amendment to Certificate of Incorporation","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Amendment to Certificate of Incorporation","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Amended and Restated Certificate of Incorporation","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Amended and Restated Certificate of Incorporation","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"In connection with the Merger, the Reneo board of directors adopted, and the Reneo stockholders approved, the amendment and restatement of Reneo’s amended and restated certificate of incorporation to change the Company’s name from “Reneo Pharmaceuticals, Inc.” to “OnKure Therapeutics, Inc.”, to create Class B Common Stock and to reclassify the Reneo Common Stock as Class A Common Stock, among other things. The amended and restated certificate of incorporation became effective at 4:02 p.m. on October 4, 2024.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"31","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Amended and Restated Bylaws","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Amended and Restated Bylaws","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"On October 4, 2024, in connection with the Merger, the Board approved the amendment and restatement of the Company’s bylaws, effective as of October 4, 2024, in order to, among other things:","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"update various provisions regarding the organization and conduct of meetings of stockholders;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"update the procedural and disclosure requirements for director nominations made and business proposals submitted by stockholders;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"update various provisions regarding the organization and conduct of meetings of the Board and its ability to act without a meeting;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"clarify certain procedures and standards with respect to the right to indemnification and advancement of expenses;","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"update provisions to align with the Company’s governance structure and remove provisions otherwise duplicative with other Company documents or the Delaware General Corporation Law; and","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"•","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"make various other updates, including clarifying, ministerial and conforming changes.","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"A further comparison of stockholders’ rights under the amended and restated certificate of incorporation and amended and restated bylaws is described in the Proxy Statement/Prospectus in the section titled “Comparison of Stockholders’ Rights,” beginning on page 320 of the Proxy Statement/Prospectus and that information is incorporated herein by reference. The foregoing descriptions of the amended and restated certificate of incorporation and amended and restated bylaws is not complete and is subject to and qualified in its entirety by reference to the amended and restated certificate of incorporation and amended and restated bylaws, copies of which are attached hereto as Exhibit 3.2 and 3.3, respectively, and incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item 5.05. Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K.","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K.","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item 5.06. Change in Shell Company Status.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"12b-2","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item 7.01. Regulation FD Disclosure.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"On October 4, 2024, the Combined Company issued a press release announcing the consummation of its previously announced Merger. A copy of such press release is furnished as Exhibit 99.4 hereto.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The information set forth under this Item 7.01, including Exhibit 99.4, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act unless expressly incorporated by specific reference in such filing.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item 9.01. Financial Statements and Exhibits.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"(a) Financial statements of businesses acquired.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The audited financial statements of Legacy OnKure as of and for the fiscal years ended December 31, 2023 and 2022 are set forth in Exhibit 99.1 hereto and are incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"32","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The unaudited financial statements of Legacy OnKure as of and for the three and six months ended June 30, 2024 are set forth in Exhibit 99.2 hereto and are incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"10-K","l":7}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"10-K”)","l":7}]}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"(b) Pro forma financial information.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"The unaudited pro forma condensed combined financial information of the Combined Company for the three and six months ended June 30, 2024 and year ended December 31, 2023 is set forth in Exhibit 99.3 hereto and is incorporated herein by reference.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"(d) Exhibits","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"EXHIBITNUMBER","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"DESCRIPTION OF DOCUMENT","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"2.1*","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Agreement and Plan of Merger, dated May 10, 2024, by and among Reneo Pharmaceuticals, Inc., Radiate Merger Sub I, Inc., Radiate Merger Sub II, LLC and OnKure, Inc. (incorporated by reference to Exhibit 2.1 to Reneo’s Current Report onForm 8-Kfiled on May 13, 2024).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"3.1","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Certificate of Amendment to Amended and Restated Certificate of Incorporation","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"3.2","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Amended and Restated Certificate of Incorporation, as amended.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"3.3","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Amended and Restated Bylaws.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"4.1","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Reneo’s Registration Statement on FormS-1,as amended, filed on April 5, 2021).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"4.2","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Amended and Restated Investors’ Rights Agreement, by and among Reneo and certain of its stockholders, dated December 9, 2020 (incorporated by reference to Exhibit 4.2 to Reneo’s Registration Statement on FormS-1,as amended, filed on March 19, 2021).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.1+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Reneo Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended, and UKSub-Plan(incorporated by reference to Exhibit 10.1 to Reneo’s Registration Statement on FormS-1,as amended, filed on April 5, 2021).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.2+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Forms of Grant Notice, Stock Option Agreement and Notice of Exercise under the Reneo Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended, and UKSub-Plan(incorporated by reference to Exhibit 10.2 to Reneo’s Registration Statement on FormS-1,as amended, filed on April 5, 2021).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.3+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to Reneo’s Registration Statement on FormS-1,as amended, filed on April 5, 2021).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.4+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Forms of (i) Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise, (ii) Stock Option Grant Notice—International, Stock Option Agreement—International and Notice of Exercise—International and(iii) Non-EmployeeDirector Stock Option Grant Notice, Stock Option Agreement and Notice ofExercise—Non-EmployeeDirector under the Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.18 to Reneo’s Annual Report on Form10-K,filed on March 27, 2023).","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"33","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"EXHIBITNUMBER","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"DESCRIPTION OF DOCUMENT","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.5+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Forms of (i) Restricted Stock Unit Award Grant Notice and Award Agreement and (ii) Restricted Stock Unit Award Grant Notice—International and Award Agreement—International under the Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to Reneo’s Registration Statement on FormS-1,as amended, filed on April 5, 2021).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.6+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise for Inducement Grant Outside of the Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to Reneo’s Quarterly Report on Form10-Q,filed on November 12, 2021).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.7+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Forms of RSU Award Grant Notice and Award Agreement (RSU Award) for Inducement Grant Outside of the Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to Reneo’s Quarterly Report on Form10-Q,filed on November 12, 2021).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.8+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Reneo Pharmaceuticals, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to Reneo’s Registration Statement on FormS-1,as amended, filed on April 5, 2021).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.9+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Reneo Pharmaceuticals, Inc. Severance Benefit Plan, as amended as of September 27, 2022, and form of Participation Agreement thereunder (incorporated by reference to Exhibit 10.2 to Reneo’s Quarterly Report on Form10-Q,filed on November 8, 2022).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.10*","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Form of Reneo Support Agreement (incorporated by reference to Exhibit 10.1 to Reneo’s Current Report on Form8-Kfiled on May 13, 2024).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.11*","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Form of OnKure Support Agreement (incorporated by reference to Exhibit 10.2 to Reneo’s Current Report on Form8-Kfiled on May 13, 2024).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.12","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Form ofLock-UpAgreement (incorporated by reference to Exhibit 10.3 to Reneo’s Current Report on Form8-Kfiled on May 13, 2024).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.13*","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Subscription Agreement dated May 10, 2024 (incorporated by reference to Exhibit 10.4 to Reneo’s Current Report on Form8-Kfiled on May 13, 2024).","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.14+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"OnKure Therapeutics, Inc. 2024 Equity Incentive Plan, and forms of agreement thereunder.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.15+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"OnKure Therapeutics, Inc. 2024 Employee Stock Purchase Plan.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.16+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"OnKure, Inc. 2011 Stock Incentive Plan, as amended, and forms of agreement thereunder.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.17+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"OnKure, Inc. 2021 Stock Incentive Plan, as amended, and forms of agreement thereunder.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.18+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"OnKure, Inc. 2023 RSU Equity Incentive Plan, and forms of agreement thereunder.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.19+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"OnKure Therapeutics, Inc. Executive Incentive Compensation Plan.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.20+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"OnKure Therapeutics, Inc. Form of Executive Employment Agreement.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.21+","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"OnKure Therapeutics, Inc. Outside Director Compensation Policy.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.22","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Form of Indemnification Agreement","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"10.23","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Registration Rights Agreement dated October 4, 2024 by and among OnKure Therapeutics, Inc. and certain parties thereto.","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"34","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"EXHIBITNUMBER","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"DESCRIPTION OF DOCUMENT","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"21.1","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Subsidiaries of OnKure Therapeutics, Inc.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"23.1","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Consent of KPMG LLP, independent registered public accounting firm.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"99.1","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Audited financial statements of Legacy OnKure as of and the fiscal years ended December 31, 2023 and 2022.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"99.2","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Unaudited interim financial statements of Legacy OnKure as of and for the three and six months ended June 30, 2024.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"99.3","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Unaudited pro forma condensed combined financial information of the Combined Company for the year ended December 31, 2023 and the three and six months ended June 30, 2024.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"99.4","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Press release dated October 4, 2024, announcing the closing of the Merger.","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"","l":8}]},{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"104","l":8},{"t":"TABLE_CELL","c":"","l":8},{"t":"TABLE_CELL","c":"Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"+","l":8},{"t":"TABLE_CELL","c":"Indicates management contract or compensatory plan.","l":8}]}]}]},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"#","l":8},{"t":"TABLE_CELL","c":"Pursuant to Item 601(b)(10) of Regulation S-K, certain portions of this exhibit have been omitted by means of marking such portions with asterisks because the Registrant has determined that the information is not material and is the type that the Registrant treats as private or confidential.","l":8}]}]}]},{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE_ROW","c":"tr","l":7,"ch":[{"t":"TABLE_CELL","c":"*","l":8},{"t":"TABLE_CELL","c":"Certain exhibits and/or schedules (and similar attachments) have been omitted pursuant to the provisions of Regulation S-K, Item 601(a)(5). The Registrant hereby undertakes to furnish supplementally to the SEC upon request by the SEC copies of any of the omitted exhibits and schedules (or similar attachments).","l":8}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"35","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"hr","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4,"ch":[{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"SIGNATURES","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.","l":6}]},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"Dated: October 8, 2024","l":6}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"CONTAINER","c":"div","l":5,"ch":[{"t":"TABLE","c":"table","l":6,"ch":[{"t":"TABLE","c":"table","l":7,"ch":[{"t":"TABLE_ROW","c":"tr","l":8,"ch":[{"t":"TABLE_CELL","c":"","l":9}]},{"t":"TABLE_ROW","c":"tr","l":8,"ch":[{"t":"TABLE_CELL","c":"ONKURE THERAPEUTICS, INC.","l":9}]},{"t":"TABLE_ROW","c":"tr","l":8,"ch":[{"t":"TABLE_CELL","c":"","l":9}]},{"t":"TABLE_ROW","c":"tr","l":8,"ch":[{"t":"TABLE_CELL","c":"By:/s/ Jason Leverone","l":9}]},{"t":"TABLE_ROW","c":"tr","l":8,"ch":[{"t":"TABLE_CELL","c":"","l":9}]},{"t":"TABLE_ROW","c":"tr","l":8,"ch":[{"t":"TABLE_CELL","c":"Name: Jason Leverone","l":9}]},{"t":"TABLE_ROW","c":"tr","l":8,"ch":[{"t":"TABLE_CELL","c":"","l":9}]},{"t":"TABLE_ROW","c":"tr","l":8,"ch":[{"t":"TABLE_CELL","c":"Title:  Chief Executive Officer","l":9}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":5},{"t":"PARAGRAPH","c":"p","l":5,"ch":[{"t":"SECTION_TITLE","c":"36","l":6}]}]}]}]}]}]}